
Pharmacally
Jemperli
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Jemperli
New Drug ApprovalJemperli Wins FDA Approval for MSI-H/dMMR Rectal CancerJemperli (dostarlimab) received FDA accelerated approval for previously untreated stage II or III MSI-H/dMMR locally advanced rectal cancer.Fact-Checked
Clinical TrialsGSK’s Jemperli Phase II Trial Shows Durable Complete Responses in dMMR Rectal Cancer, Supporting Potential Non-Surgical TreatmentGSK reported positive interim Phase II AZUR-1 results showing Jemperli (dostarlimab) achieved durable clinical complete responses in patients with stage II/III dMMR/MSI-H locally advanced rectal cancer.Fact-Checked
Health TidingsGSK stands firm on Jemperli as AnaptysBio seeks to reclaim rightsGSK and TESARO are seeking to retain rights to Jemperli (dostarlimab) amid an ongoing dispute with AnaptysBio, which has challenged the terms of their 2014 licensing agreement.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.